Alfred Clinical Trials

Alfred Health has more than 700 open trials across 20 clinical disciplines, our clinical trial portfolio is one of the largest in the country.

Clear filter
604 clinical trials found
Clinical trials

IDE196-009

(NEO)ADJUVANT IDE196 (DAROVASERTIB) IN PATIENTS WITH LOCALIZED OCULAR MELANOMA (NCT05907954)

Currently recruiting

GOlDiLOX

[NHL37] An open-label, single-arm, phase 2 trial of GlOfitamab anD pIrtobrutinib [LOXo-305] in patients with mantle cell lymphoma and prior exposure to a BTK inhibitor – GOlDiLOX (NCT05833763)

Currently recruiting

2SHOTS

2-fraction Stereotactic ultra-HypOfractionated radiation Therapy of the proState (ACTRN12625000198426)

Currently recruiting

CORE

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of ISIS 678354 Administered Subcutaneously to Patients with Severe Hypertriglyceridemia (NCT05079919)

Currently recruiting

CLOU064M12301

A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, safety, and tolerability of remibrutinib (LOU064) in Chronic Inducible Urticaria (CINDU) in adults inadequately controlled by H1-antihistamines (NCT05976243)

Currently recruiting

ADAPT-TDM

A beta-lactam antibiotic Dose Adaptation Pilot randomised controlled Trial utilising Therapeutic Drug Monitoring (ADAPT-TDM) (ACTRN12623000032651)

Currently recruiting

ZEPFHR-MM

A Centralized Platform study for Functional High Risk Multiple Myeloma (ACTRN12625000429459)

Currently recruiting

REFINE

A Dose Adjusted, Open Label, Multi-Centre Study to Determine the Safety, Tolerability and Pharmacokinetics of STC3141 Administered as an Infusion forup to 72 hours in Subjects with Sepsis and Normal or Compromised Renal Function in an Intensive Care Unit (REFINE) (ACTRN12620000716965)

Recently completed/closed

FIBRONEER 14

A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) (NCT05321069)

Currently recruiting

FIBRONEER 23

A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) (NCT05321082)

Currently recruiting

FINER

A Double- Blinded Placebo Controlled Randomized Phase III Trial of Fulvestrant and Ipatasertib as Treatment for Advanced/ Metastatic Her 2 Negative and Oestrogen Receptor Positive (ER+) Breast Cancer following Progression on first line CD4/6 Inhibitor and Aromatase Inhibitor (Finer) (NCT04650581)

No longer recruiting

RESPIR-102

A Double-Blind, Active-Controlled, Multiple-Ascending Dose, Phase 1b Study of Aerosolized RSP-1502 Delivered Via the PARI LC Plus® Nebulizer in Subjects with Cystic Fibrosis and Chronic Pseudomonas aeruginosa Lung Infection (NCT06016088)

Currently recruiting

CRVOMed Study

A Double-Blind, Placebo-Controlled, Proof-of-Concept Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod on Recovery after Ischemic Stroke (NCT06987643)

Currently recruiting

PC_ASP_006

A double-blind, randomized, placebo-controlled study to assess the safety and efficacy of nebulized PC945 when added to systemic antifungal therapy for the treatment of refractory invasive pulmonary aspergillosis (NCT05238116)

Currently recruiting

MARINUS SE [RAISE]

A double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of intravenous ganaxolone in status epilepticus (NCT04391569)

Currently recruiting

Seelos SLS-005

A double-blind, randomized, placebo-controlled trial to assess safety and efficacy of SLS-005 (trehalose injection, 90.5 mg/mL for intravenous infusion) for the treatment of adults with spinocerebellar ataxia (NCT05490563)

Currently recruiting

UCB STACCATO ALPRAZOLAM-DB

A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Outpatient, Parallel-Group Study to Assess the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures (NCT05077904)

Currently recruiting

E-TAN

A double-blinded randomised placebo-controlled trial of estradiol: investigating the effect on disordered eating symptoms of women with anorexia nervosa (ACTRN12623000897662)

Currently recruiting

AN4

A double-blinded, 4-arm, covariate-adjusted adaptive clinical trial evaluating the efficacy of novel pharmacological agents for the treatment of anorexia nervosa in individuals aged 16 and over (ACTRN12623001019695p)

Currently recruiting

TRITON

A Feasibility Trial of Tranexamic Acid for Necrotising Soft-Tissue Infections (ACTRN12621001423808)

Currently recruiting
1 2 3